10:03 , Aug 13, 2018 |  BC Extra  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Monday with a $31 million series A round. Participating in the...
18:50 , Aug 10, 2018 |  BC Week In Review  |  Company News

Janssen, Immune Biosolutions partner to discover, develop antibodies for cancer

Immune Biosolutions Inc. (Sherbrooke, Quebec) and the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to discover and develop antibodies against multiple undisclosed cancer targets. The partners will utilize Immune Biosolutions' Nebula antibody...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera, respectively....
22:00 , Aug 9, 2018 |  BC Extra  |  Politics & Policy

China releases list of overseas drugs eligible for Priority Review

China’s Drug Evaluation Center posted a list of 48 drugs already approved in the U.S., EU or Japan that could be eligible for Priority Review in China. Last December, China's State Drug Administration released guidance to...
19:12 , Aug 9, 2018 |  BC Extra  |  Company News

Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash. Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera, respectively....
23:48 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting IKKα or its activator MAP3K14 could help treat liver disease. In a partial hepatectomy mouse model of liver injury, hepatocyte-specific knockout of MAP3K14 or IKKα increased hepatocyte proliferation and...
19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
17:51 , Aug 3, 2018 |  BC Week In Review  |  Company News

Celltrion wins another biosimilar infliximab lawsuit

A federal judge ruled July 30 that biosimilar Inflectra infliximab-dyyb from Celltrion Inc. (KOSDAQ:068270) does not infringe a patent from Johnson & Johnson (NYSE:JNJ) covering autoimmune drug Remicade infliximab. The decision follows a previous Celltrion...
21:08 , Aug 2, 2018 |  BC Extra  |  Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes...